Le Lézard
Classified in: Health, Science and technology
Subjects: PDT, TRI

Akeso Announces Launch of U.S. Investigator-Initiated Study of Cadonilimab (PD-1/CTLA-4 Bispecific Antibody)

HONG KONG, Dec. 6, 2021 /PRNewswire/ -- Today, Akeso, Inc. (9926.HK) announced that the company will support an investigator-initiated study (IIS) to evaluate the efficacy and safety of Akeso's novel, first-in-class anti-PD-1/CTLA-4 bispecific antibody, cadonilimab, for the treatment of neuroendocrine cervical carcinoma in the United States.

Following a review of the efficacy data from the Akeso-sponsored Phase 2 clinical trial of Cadonilimab in recurrent or metastatic cervical cancer, this study was initiated and will be led by Michael Frumovitz, M.D., M.P.H., FACOG, Professor of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center.


Cadonilimab (AK104) is a novel, potential next-generation, first-in-class bispecific PD-1/ CTLA-4 immunooncology backbone drug developed by Akeso Biopharma. It is one of Akeso's core assets within the company's broad pipeline of therapeutic monoclonal antibodies. It is being developed for various indications such as lung cancer, gastric cancer, hepatocellular carcinoma, cervical cancer, esophageal squamous carcinoma, and nasopharyngeal carcinoma. Clinical data from ongoing studies demonstrate that Cadonilimab has promising efficacy against a wide variety of tumor types while exhibiting lower toxicity and a more favorable safety profile when compared to the co-administration of anti-PD-1 plus anti-CTLA-4 therapies.


Akeso, Inc. (9926.HK) is a biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of new innovative antibody drugs that are affordable to patients worldwide. Since the Company's establishment, the Company has established an end-to-end comprehensive drug development platform (ACE Platform) and system, encompassing fully integrated drug discovery and development functions, including target validation, antibody drug discovery and development, CMC production process development, and GMP compliant scale production. The Company has also successfully developed a bispecific antibody drug development technology (Tetrabody technology). The Company currently has a pipeline of over 20 innovative drugs for the treatment of major diseases like tumors, autoimmune diseases, inflammation and metabolism diseases, 13 of which have entered clinical stage, including two first-in-class bispecific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF). The Company's vision is to become a global leading biopharmaceutical company through research and development of high efficacy and breakthrough new drugs that are first-in-class and best-in-class therapies.

SOURCE Akeso,Inc.

These press releases may also interest you

at 10:50
Cadence Design Systems, Inc. today announced that Microchip has deployed the Cadence® Palladium® Z2 Enterprise Emulation Platform for the development of their next generation ASIC products targeting high performance and scalable SoC solutions for...

at 10:47
Medalogix, a premier data science and machine learning platform focused on the advancement of patient care within the home health, palliative, and hospice care setting, is proud to be Certifiedtm by Great Place to Work®. The prestigious award is...

at 10:45
Marcus Jadotte has joined Crowley as senior vice president of government relations, leading the company's advocacy activities across all its businesses. Jadotte will spearhead the company's continuing advocacy for laws and regulations that support...

at 10:45
The "Global Single Cell Genomics Market Forecasts by End-user & Technology with Executive & Consultant Guides, Including Customized Forecasting and Analysis with COVID-19 Updates" report has been added to ResearchAndMarkets.com's offering. Single...

at 10:45
Greenlight Guru, pioneer of the only dedicated Medical Device Success Platform (MDSP), today announced its acquisition of CanvasGT, a software company that creates a modern solution for medical device companies to collaborate on initial designs and...

at 10:37
Nativo, a leading content technology platform, announced the appointment of Rob Leff to the role of Chief Financial Officer. Rob will lead the finance organization for Nativo and act as a key business partner to Chief Executive Officer Justin Choi....

News published on 6 december 2021 at 19:20 and distributed by: